Status:

COMPLETED

Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma

Lead Sponsor:

Sumitomo Pharma America, Inc.

Conditions:

Asthma

Eligibility:

All Genders

4-11 years

Phase:

PHASE3

Brief Summary

Study of Daily Dosing with Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects with Asthma

Detailed Description

This was a Phase III, double-blind, randomized, placebo- and active-controlled, multicenter, parallel-group study of up to 6 weeks in duration. Seven days of QID single-blind, placebo administration (...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Subject and subject's p/l guardian must be willing and able to comply with the study procedures and visit schedules
  • Subject, male or female, between the ages of 4 to 11 yrs
  • Female subjects 8 yrs or older will have a negative serum pregnancy test
  • Must have a documented diagnosis of asthma for a minimum of 6 months prior to study start
  • Must have stable baseline asthma and have been using a B-adrenergic agonist, and/or anti-asthma anti-inflammatory medication, and/or over-the-counter asthma medication for at least 6 mos. prior to study start
  • Must be in good health with the exception of reversible airways disease and not suffering from any chronic condition that might affect their respiratory function
  • Must have a chest X-ray that is not diagnostic of pneumonia, atelectasis, pulmonary fibrotic disease, pneumothorax, chronic obstructive pulmonary disease etc
  • Subject's p/l guardian must be able to complete the diary cards and medical event calendars reliably on a daily basis, understand dosing instructions and questionnaire completion, and demonstrate how to use the MiniWright PEF meter
  • Exclusion Criteria
  • Female subject who is pregnant or lactating
  • Have participated in an investigational drug study within 30 days prior to study start, or who is currently participating in another clinical trial
  • Schedule prevents him or her from taking the first daily dose of study medication and/or starting study visits before 9 AM
  • Have travel commitments during the study that would interfere with trial measurements or compliance or both
  • Have a history of hospitalization for asthma within 60 days prior to study start, or who is scheduled for in-patient hospitalization, including elective surgery during the course of the trial
  • Have a known sensitivity to levalbuterol or racemic albuterol, or any of the excipients contained in any of these formulations
  • Subject using any prescription drug with which albuterol sulfate administration is contraindicated
  • Have currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 3 mos. prior to study start
  • Have a history of cancer
  • Subject with hyperthyroidism, diabetes, hypertension, cardiac diseases or seizure disorders that currently are not well controlled by medication or that may interfere with the successful completion of this protocol
  • Have a history of substance abuse or drug abuse within 12 months preceding V1 or a positive urine drug screening at study start
  • Have a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis
  • Has suffered from a clinically significant upper or lower respiratory tract infection in the 2 wks prior to study start
  • Have a history of cigarette smoking or use of any tobacco products
  • Subject who is a relative of a staff member

Exclusion

    Key Trial Info

    Start Date :

    December 1 2002

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 1 2003

    Estimated Enrollment :

    80 Patients enrolled

    Trial Details

    Trial ID

    NCT00073814

    Start Date

    December 1 2002

    End Date

    June 1 2003

    Last Update

    February 22 2012

    Active Locations (45)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 12 (45 locations)

    1

    Adolescent & Pediatric Associates, PC

    Montgomery, Alabama, United States, 36116

    2

    The Children's Clinic of Jonesboro, PA

    Jonesboro, Arkansas, United States, 72401

    3

    Integrated Research Group

    Corona, California, United States, 92879

    4

    Allergy & Asthma Specialists Medical Group

    Huntington Beach, California, United States, 92647